Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:52 UTC |
---|
HMDB ID | HMDB0015104 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Alosetron |
---|
Description | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. |
---|
Structure | CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2 InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) |
---|
Synonyms | Value | Source |
---|
2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one | ChEBI | Alosetron HCL | HMDB | Alosetron monohydrochloride | HMDB | Lotronex | HMDB | Alosetron hydrochloride | HMDB | 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride | HMDB | GlaxoSmithKline brand OF alosetron hydrochloride | HMDB |
|
---|
Chemical Formula | C17H18N4O |
---|
Average Molecular Weight | 294.351 |
---|
Monoisotopic Molecular Weight | 294.148061218 |
---|
IUPAC Name | 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-1-one |
---|
Traditional Name | alosetron |
---|
CAS Registry Number | 122852-42-0 |
---|
SMILES | CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2 |
---|
InChI Identifier | InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) |
---|
InChI Key | JSWZEAMFRNKZNL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-alkylindoles. N-alkylindoles are compounds containing an indole moiety that carries an alkyl chain at the 1-position. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Indoles and derivatives |
---|
Sub Class | N-alkylindoles |
---|
Direct Parent | N-alkylindoles |
---|
Alternative Parents | |
---|
Substituents | - N-alkylindole
- Indole
- N-methylpyrrole
- Substituted pyrrole
- Benzenoid
- Imidazole
- Heteroaromatic compound
- Pyrrole
- Vinylogous amide
- Azole
- Tertiary carboxylic acid amide
- Lactam
- Carboxamide group
- Carboxylic acid derivative
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxygen compound
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.44 g/L | Not Available | LogP | 2 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Alosetron,1TMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C | 2934.9 | Semi standard non polar | 33892256 | Alosetron,1TMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C | 2796.3 | Standard non polar | 33892256 | Alosetron,1TMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C | 3550.8 | Standard polar | 33892256 | Alosetron,1TBDMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C(C)(C)C | 3182.1 | Semi standard non polar | 33892256 | Alosetron,1TBDMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C(C)(C)C | 2990.6 | Standard non polar | 33892256 | Alosetron,1TBDMS,isomer #1 | CC1=C(CN2CCC3=C(C2=O)C2=CC=CC=C2N3C)N=CN1[Si](C)(C)C(C)(C)C | 3611.6 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Alosetron GC-MS (Non-derivatized) - 70eV, Positive | splash10-054p-9640000000-36ec950b2b5a4de0d766 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Alosetron GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Alosetron , positive-QTOF | splash10-0udi-0390000000-3b813a9458d2bce7516f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alosetron 35V, Positive-QTOF | splash10-0udi-3390000000-9994f53a2714bf016b00 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 10V, Positive-QTOF | splash10-0002-5090000000-aa22d1e533a9ade9a631 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 20V, Positive-QTOF | splash10-0002-9470000000-de378c4e797603ddebd5 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 40V, Positive-QTOF | splash10-0udj-9000000000-4320dc79a39aa798ebed | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 10V, Negative-QTOF | splash10-0006-0090000000-61b91fd4d7827b2dee3c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 20V, Negative-QTOF | splash10-0006-1690000000-1c0db2dce26ffd0716f7 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 40V, Negative-QTOF | splash10-001i-4900000000-bac7a8e86a49765da618 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 10V, Positive-QTOF | splash10-0002-0090000000-0a33faab2e775c338d55 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 20V, Positive-QTOF | splash10-0002-0090000000-6aa9a0fa5a9c1aeeb778 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 40V, Positive-QTOF | splash10-001i-9320000000-27c420ad3c1a98b56add | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 10V, Negative-QTOF | splash10-0006-0090000000-abdd2e02132168abe3fa | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 20V, Negative-QTOF | splash10-0006-0190000000-c8bf656d3129fa7c6a2c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alosetron 40V, Negative-QTOF | splash10-03di-0290000000-dacd12d29c5302eb8887 | 2021-10-11 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00969 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00969 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00969 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 2015 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Alosetron |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 2099 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 253342 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. [PubMed:14596662 ]
- Camilleri M: Pharmacology and clinical experience with alosetron. Expert Opin Investig Drugs. 2000 Jan;9(1):147-59. [PubMed:11060667 ]
- Rahimi R, Nikfar S, Abdollahi M: Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008 May;30(5):884-901. doi: 10.1016/j.clinthera.2008.05.002. [PubMed:18555935 ]
- Lewis JH: Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. doi: 10.1586/egh.09.72. [PubMed:20136586 ]
- Andresen V, Hollerbach S: Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283-92. [PubMed:15061683 ]
|
---|